ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that Erica Barnell, MD, PhD, Geneoscopy’s Chief Medical & Science Officer, will present at two important healthcare conferences, showcasing advancements in colorectal cancer (CRC) screening and early detection.
Cambridge Healthtech Institute’s Early Cancer Surveillance Dx Roundtable Breakout Discussions
- Topic: “Blood-based Colorectal Cancer Screening Tests – Ready for Prime-Time as a First Line Screening Test?”
- Date & Time: Aug. 21, 2024, at 9:30 a.m. EDT
- About: The presentation will shed light on the latest data and perspectives on blood-based CRC screening tests and examine recent clinical trial results. The discussion will review the benefits of blood tests, including higher patient compliance and broader demographic reach, while also addressing the challenges posed by lower sensitivity in detecting stage 1 cancer and pre-cancers compared to standard tests like colonoscopy and at-home, stool-based screening tests.
American College of Gastroenterology Virtual Grand Rounds
- Topic: “What the Practicing GI Clinician Needs to Know About Stool-Based Testing”
- Date & Time: Aug. 22, 2024, at 12:00 p.m. and 8:00 p.m. EDT (a pre-recorded session will also be available on ACG Education Universe on Aug. 30, 2024)
- About: In this discussion, Dr. Barnell and Dr. Thomas F. Imperiale, Indiana University School of Medicine and the Regenstrief Institute, will delve into the significance of stool-based testing, covering its use and implications, and role for practicing gastroenterologists. The session will explore the comparative advantages of stool-based tests over blood tests and colonoscopies, examine how sensitivity and specificity rates affect test selection, and discuss key factors influencing the recommendation of stool-based testing to patients.
“I am honored to participate in these important discussions alongside leading researchers to help advance the field of gastroenterology and early CRC detection,” Dr. Barnell said. “By exploring the latest in stool-based and blood-based testing, we are paving the way for more accurate, accessible, and patient-friendly screening methods. Our goal is to ensure that patients benefit from these innovations, leading to earlier cancer detection, better treatment outcomes, and ultimately, improved survival rates.”
More than 44 million Americans at average risk for CRC remain unscreened despite screening’s vital role in early detection and prevention. Access to reliable options for screening enhances the ability to detect disease early and provides valuable information to guide personalized treatment options. Geneoscopy’s FDA-approved noninvasive CRC screening test, ColoSense™, is the first to use an RNA-based assay, offering a dynamic view of disease activity.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense™ test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
